# DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Source: https://onco.cc/trials/nct04567420/  
OnCo record `nct04567420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Criterium, Inc., active and no longer recruiting.

## Summary

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) is a phase 2 interventional study registered as NCT04567420 by Criterium, Inc., with 70 participants enrolled, started 2021-02-09 and due to reach its primary completion in 2027-12-31. Interventions recorded: Palbociclib, Fulvestrant and Adjuvant Therapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04567420
- Phase: 2
- Setting: A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Sponsor: Criterium, Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT04567420: https://clinicaltrials.gov/study/NCT04567420

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Palbociclib](https://onco.cc/drugs/palbociclib/)

---
JSON: https://onco.cc/api/v1/entities/nct04567420.json